Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 905 / https://doi.org/10.3332/ecancer.2019.905

Review

The use of intravesical BCG in urothelial carcinoma of the bladder

The high recurrence and progression rates of non-muscle invasive bladder cancer (NMIBC) have led investigators to study the use of intravesical therapy in order to prevent them. Bacillus Calmette–Guérin (BCG) has been successfully used for this indication to treat NMIBC for more than four decades.

BCG is the only intravesical agent shown to reduce the risk of progression of NMIBC to muscle-invasive disease. Despite over 40 years of clinical use, the precise mechanism of action for what has often been considered the most successful cancer immunotherapy in humans remains largely unknown.

Unfortunately, BCG therapy is not a universal panacea and it still fails in up to 40% of patients. Many of these patients, especially in the high-risk category (T1 high-grade disease, carcinoma in situ) will require aggressive therapy like cystectomy or in selected cases, bladder-sparing options like chemo-radiation. Indeed, there is no gold standard intravesical treatment after BCG failure.

Keywords: bladder cancer, bacillus Calmette–Guérin, non-muscle invasive bladder cancer, urothelial carcinoma, intravesical therapy

Loading Article Metrics ... Please wait

Related articles

Review: Innovative approaches for cancer treatment: current perspectives and new challenges

Abstract | Full Article | PDF Published: 10 Sep 2019 / https://doi.org/10.3332/ecancer.2019.961

Case Report: Acute myeloid leukaemia presenting as acute liver failure—a case report and literature review

Abstract | Full Article | PDF Published: 09 Sep 2019 / https://doi.org/10.3332/ecancer.2019.960

Review: Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?

Abstract | Full Article | PDF Published: 27 Aug 2019 / https://doi.org/10.3332/ecancer.2019.959

Review: Non-gastrointestinal stromal tumours soft tissue sarcomas: an update

Abstract | Full Article | PDF Published: 13 Aug 2019 / https://doi.org/10.3332/ecancer.2019.958

Clinical Study: Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis

Abstract | Full Article | PDF Published: 06 Aug 2019 / https://doi.org/10.3332/ecancer.2019.957



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation